https://www.selleckchem.com/pr....oducts/cerdulatinib-
2% vs. 72.8%, P=0.015), longer stent patency (P=0.02), and lower number of re-interventions for stent dysfunction (0.27±0.65 vs. 1.27±1.1, P=0.001) than the PS group. The adverse events of EBD, operation time, volume of intraoperative bleeding, postoperative hospitalization, postoperative adverse events and medical costs did not significantly differ between the two groups. In patients with BRPC for preoperative biliary drainage, stent dysfunction occurred less frequently with FCSEMSs than with PSs. In addition, FC
Like
Comment
Share
